Back to top
more

NovoCure Limited (NVCR)

(Delayed Data from NSDQ)

$22.01 USD

22.01
1,483,612

-0.26 (-1.17%)

Updated May 31, 2024 04:00 PM ET

After-Market: $22.00 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NVCR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

NovoCure Limited [NVCR]

Reports for Purchase

Showing records 201 - 210 ( 210 total )

Company: NovoCure Limited

Industry: Medical Services

Record: 201

04/19/2016

Daily Note

Pages: 40

1Q16 MedTech Preview: Stable Trends; Prefer the Oversold Names With Solid Fundamentals

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 202

04/05/2016

Daily Note

Pages: 5

NVCR Roadshow Takeaways Support Our Positive Stance; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 203

03/01/2016

Company Report

Pages: 8

4Q15 EPS and 2016 Outlook, plus Key Takeaways from our Expert Dinner, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 204

01/20/2016

Daily Note

Pages: 5

Positive Survival Data from PANOVA Study in Pancreatic Cancer, Data Further Supports Broad Utility of TTFields Therapy

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 205

01/11/2016

Company Report

Pages: 6

Preannounces Positive Preliminary 4Q Results; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 206

01/08/2016

Daily Note

Pages: 24

MedTech 2016 Outlook: Risk/Reward Looks Attractive

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 207

12/15/2015

Daily Note

Pages: 4

Pivotal Study in Frontline GBM Published in JAMA Should Drive Awareness, Adoption, and Reimbursement of Optune, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 208

11/23/2015

Daily Note

Pages: 7

Updated Data at SNO Supports Optune Rechallenge and Long Duration of Use, Reiterate OUTPERFORM and $30 PT

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 209

10/27/2015

Company Report

Pages: 33

Initiating Coverage with an OUTPERFORM and a $30 PT

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 210

10/27/2015

Company Report

Pages: 33

Initiating Coverage with an OUTPERFORM and a $30 PT; an Impressive New Modality for Cancer Treatment Emerges

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party